BridgeBio Soars on Positive Trial Data as Moderna Navigates post-vaccine Challenges
San Francisco, CA - BridgeBio Pharma experienced a significant boost this week following promising Phase 3 trial results, while Moderna faces headwinds as it adjusts too life after its blockbuster COVID-19 vaccine. The contrasting fortunes of the two biotech companies highlight the volatile nature of the industry and the challenges of sustaining growth in a rapidly evolving landscape.
BridgeBio’s positive data, revealed this week, centers on its treatment for limb-girdle muscular dystrophy, a rare genetic disorder. The results offer hope for patients with limited treatment options and validate the company’s focused approach to developing therapies for genetic diseases. Simultaneously, Moderna is grappling with a downturn after the unprecedented success of its COVID-19 vaccine, prompting questions about its future pipeline and strategic direction. these developments underscore the critical importance of diversification and innovation in the biotech sector, were fortunes can shift dramatically based on clinical trial outcomes and market dynamics.
This week on STAT’s biotech podcast,”The Readout Loud,” BridgeBio CEO Neil Kumar discussed the company’s encouraging Phase 3 readouts. The conversation delved into the implications of the data and the potential path forward for the treatment. The podcast also featured STAT colleague Jason Mast, who analyzed Moderna’s struggles following the peak of the pandemic and the subsequent decline in demand for its COVID-19 vaccine.
Beyond these key stories, “the Readout Loud” covered Novo Nordisk‘s bid to acquire biotech company Metsera, and recent setbacks in the field of genetic medicines, specifically Intellia’s decision to pause its gene-editing trials.
Listeners can find ”The Readout Loud” on Apple Podcasts, Spotify,or wherever they get their podcasts.
For further details:
* BridgeBio’s data: https://www.statnews.com/2025/10/27/bridgebio-limb-girdle-muscular-dystrophy/
* Moderna analysis: https://www.statnews.com/2025/10/30/moderna-rise-fall-biotech-analysis-from-pandemic-rise-to-mrna-crash/
* Novo Nordisk’s bid: https://www.statnews.com/2025/10/30/novo-nordisk-metsera-pfizer-acquisition-offer-bidding-war/
* intellia’s trial pause: https://www.statnews.com/2025/10/27/intellia-gene-editing-trial-pause/
